Lumida
/AZN
⌘K
AstraZeneca PLC

AstraZeneca PLC

AZN
$168.90USD-0.23%-0.39 today

MARKET CAP

144.9B

P/E (TTM)

18.3x

FWD P/E

15.1x

DAY RANGE

$167 – $170

52W RANGE

$137
$213

AI Summary

Stalk
TrimMedium

AZN remains in a Stage 4 decline with a bearish medium-term bias after the support failure in mid-July. Price sits below the 9 and 20 EMAs and has been unable to reclaim these levels on the recent oversold bounce, suggesting sell-side control. The long-term uptrend is intact above the rising 200 DMA, capping risk, but rallies need to be watched for rejections at falling EMAs to maintain the bearish stance. A decisive reclaim and close above the EMAs would warrant a reassessment.

  • Q1 2025 revenue rose 10% YoY to $11.7 B; core EPS up 21% to $2.49.
  • Oncology sales jumped 16% YoY to $6.8 B, led by strong Infinzi uptake.
  • Wainua trial failure reduces near-term revenue visibility.
Full analysis →
Insider Trades4 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Jul 6, 2026BuyAZNMani Sharma2$190.43$144.9B-20.60%+23.08%$380.86+0.01%Sell Now
Jun 8, 2026BuyAZNMani Sharma1$179.75$144.9B-20.60%+23.08%$179.75+0.01%Sell Now
May 20, 2026SellAZNMani Sharma11,893$185.78$144.9B-20.60%+23.08%$2.2M-38.17%Sell Now
Apr 7, 2026BuyAZNMani Sharma2$191.16$144.9B-20.60%+23.08%$382.31+0.00%Sell Now